136 related articles for article (PubMed ID: 3243982)
1. CA 19-9 assay in patients with extrahepatic cholestatic jaundice.
Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V
Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
3. [Laboratory diagnosis of tumors of the pancreato-biliary area in patients with mechanical jaundice].
Skvortsov SV; Lytsar' BN; Kalinin AV; Dolinskiĭ AG
Klin Med (Mosk); 1992; 70(5-6):21-3. PubMed ID: 1279265
[TBL] [Abstract][Full Text] [Related]
4. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
5. [Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?].
Nakad A; Colombel JF; Geubel AP; Cerulus G; Farchakh E; Degrez T; Janssen J; Cortot A; Paris JC; Dive C
Acta Gastroenterol Belg; 1989; 52(1-2):17-22. PubMed ID: 2618531
[TBL] [Abstract][Full Text] [Related]
6. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
7. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
8. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
10. A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis.
Pasanen PA; Partanen KP; Pikkarainen PH; Alhava EM; Janatuinen EK; Pirinen AE
Eur J Surg; 1993 Jan; 159(1):23-9. PubMed ID: 8095802
[TBL] [Abstract][Full Text] [Related]
11. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
Pålsson B; Masson P; Andrén-Sandberg A
Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
15. Dilemma of elevated CA 19-9 in biliary pathology.
Tsen A; Barbara M; Rosenkranz L
Pancreatology; 2018 Dec; 18(8):862-867. PubMed ID: 30249386
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of CA 50 assay as a tumor marker].
Hara K; Mitsuhashi F; Ohkura H
Nihon Rinsho; 1990 Feb; 48 Suppl():971-3. PubMed ID: 2192182
[No Abstract] [Full Text] [Related]
17. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
18. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis of cancer of the organs of the pancreatoduodenal zone accompanied by jaundice].
Kasum'ian SA; Cherniavskiĭ AA; Troitskiĭ KI; Shitov AN; Mezinov VV
Khirurgiia (Mosk); 1988 Nov; (11):65-8. PubMed ID: 3210627
[No Abstract] [Full Text] [Related]
20. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50.
Molina LM; Díez M; Cava MT; Maestro ML; Ortega MD; Mendíz JG; Prego A; De Diego JA; Balibrea JL
Int J Biol Markers; 1990; 5(3):127-32. PubMed ID: 2286776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
